Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

21. Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. Full Text available with Trip Pro

Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. Schizophrenia is a severe mental health condition that is characterised by positive symptoms, such as hallucinations and delusions; negative symptoms, such as flattened affect, thought disorder (disrupted speech), and lack of motivation; and cognitive symptoms, such as problems with memory and attention. Schizophrenia can occur as an isolated episode, or as a recurring cycle of remission (...) and relapse, and is associated with impairment in psychosocial and occupational functioning.Although antipsychotic drugs are the main treatment for people with schizophrenia, in most countries mental health services usually provide a range of add-on interventions, including occupational therapy. This is a complex intervention designed to support and enable continued participation in daily life through engagement in activities and occupations meaningful to the individual. Occupational therapists

2018 Cochrane

22. Schizophrenia

Schizophrenia Top results for schizophrenia - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for schizophrenia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

23. Schizophrenia

Schizophrenia Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

24. Mirtazapine adjunct for people with schizophrenia. Full Text available with Trip Pro

Mirtazapine adjunct for people with schizophrenia. Many individuals who have a diagnosis of schizophrenia experience a range of distressing and debilitating symptoms. These can include positive symptoms (such as delusions, hallucinations, disorganised speech), cognitive symptoms (such as trouble focusing or paying attention or using information to make decisions), and negative symptoms (such as diminished emotional expression, avolition, alogia, and anhedonia). Antipsychotic drugs are often (...) only partially effective, particularly in treating negative symptoms, indicating the need for additional treatment. Mirtazapine is an antidepressant drug that when taken in addition to an antipsychotic may offer some benefit for negative symptoms.To systematically assess the effects of mirtazapine as adjunct treatment for people with schizophrenia.The Information Specialist of Cochrane Schizophrenia searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including registries

2018 Cochrane

25. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Full Text available with Trip Pro

Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Many people with schizophrenia do not respond to an initially prescribed antipsychotic drug. In such cases, one treatment strategy could be to increase the antipsychotic dose; and another strategy could be to switch to a different antipsychotic drug.To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non-responsive people (...) with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials.All relevant randomised controlled trials (RCTs) comparing increasing the antipsychotic dose versus switching to a different antipsychotic drug for people with schizophrenia who have not responded to their initial antipsychotic treatment.At least two review authors independently extracted data. We analysed dichotomous

2018 Cochrane

26. Brexpiprazole (Rexulti) - schizophrenia

Brexpiprazole (Rexulti) - schizophrenia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2018 Health Canada - Drug and Health Product Register

27. Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance

Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance Relative to SSRI users, SSRI–statin users have fewer psychiatric hospital contacts and no increase in suicidal behaviour or all-cause mortality | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please

2018 Evidence-Based Mental Health

28. Cognitive therapy for schizophrenia

Cognitive therapy for schizophrenia Cognitive therapy for schizophrenia Cognitive therapy for schizophrenia Leas B, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Leas B, Umscheid CA. Cognitive therapy for schizophrenia. Philadelphia: Center for Evidence-based Practice (CEP). 2018 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Cognitive Therapy; Humans; Schizophrenia Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32018000158 Date abstract record published 16/04/2018 Health Technology Assessment (HTA) database Copyright © 2019

2018 Health Technology Assessment (HTA) Database.

29. Cost-effectiveness of cognitive–behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study Full Text available with Trip Pro

Cost-effectiveness of cognitive–behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study Sleep problems are pervasive in people with schizophrenia, but there are no clinical guidelines for their treatment. The Better Sleep Trial (BEST) concluded that suitably adapted cognitive-behavioural therapy (CBT) is likely to be highly effective, although its cost-effectiveness is unknown.To assess the potential cost-effectiveness of CBT for sleep (...) (95% CI -10 529 to 4736) and £1227 (95% CI -10 395 to 5361) lower costs from National Health Service and societal perspectives, respectively. The estimated value of collecting more information about the effects of the CBT on costs and QALYs was approximately £87 million.CBT for insomnia in people with schizophrenia is effective and potentially cost-effective. A larger trial is needed to provide clear evidence about its cost-effectiveness.Patients with schizophrenia have multiple complex health

2018 BJPsych open

30. Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City Full Text available with Trip Pro

Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City Non-attendance to clinic appointments is associated with poorer treatment outcomes. There is a dearth of information about missed first clinic appointments among patients with schizophrenia in Nigeria.To determine the prevalence, correlates and reasons for missed first appointment among out-patients with schizophrenia (...) at the Federal Neuro-Psychiatric Hospital, Benin City, Nigeria.A cross-sectional descriptive study among 275 out-patients with schizophrenia, using the Mini International Neuro-Psychiatric Interview and the Brief Psychiatric Rating Scale.The prevalence of missed first appointment was 31%. Higher BPRS score was associated with missing the appointment. The main reasons for missed appointments were: forgetting the appointment date and patient's refusal to come to the clinic.Missed first out-patient clinic

2018 BJPsych open

31. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics Full Text available with Trip Pro

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics The objective of this study was to compare persistence, costs, and healthcare resource utilization in patients with schizophrenia and cardiometabolic comorbidities treated with once-monthly paliperidone palmitate or an oral atypical antipsychotic.Medicaid data from six states (07/2009-03/2015) were used to identify (...) adults with schizophrenia and cardiometabolic comorbidities initiated on once-monthly paliperidone palmitate or an oral atypical antipsychotic (index date) on 01/2010 or after. Persistence to index medication at 12 months (no gap ≥ 90 days) was compared between patients taking once-monthly paliperidone palmitate and an oral atypical antipsychotic using Chi-squared tests. The 12-month post-index healthcare costs and healthcare resource utilization were compared using multivariate ordinary least

2018 Drugs - real world outcomes

32. Cariprazine (Reagila) for the treatment of schizophrenia

Cariprazine (Reagila) for the treatment of schizophrenia Cariprazine (Reagila®) for the treatment of schizophrenia | Report | National Health Care Institute You are here: Cariprazine (Reagila®) for the treatment of schizophrenia Search within English part of National Health Care Institute Search Cariprazine (Reagila®) for the treatment of schizophrenia The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out a substantive (...) assessment of the medicinal product Reagila® to determine whether it can be included in the Medicine Reimbursement System (GVS). And if so, if Cariprazine (Reagila®) is interchangeable with a medicinal product that is already included in the GVS. Advice Reagila® is an atypical antipsychotic, registered for the treatment of schizophrenia in adult patients. Based on the criteria for interchangeability, the Zorginstituut concludes that Reagila® is interchangeable with drugs that are already included

2018 National Health Care Institute (Zorginstituut Nederland)

33. Causes and risk factors: Women with schizophrenia are at increased risk of breast cancer

Causes and risk factors: Women with schizophrenia are at increased risk of breast cancer Women with schizophrenia are at increased risk of breast cancer | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Women with schizophrenia are at increased risk of breast cancer Article Text Commentary Causes and risk factors Women with schizophrenia are at increased risk of breast cancer Alison R Yung 1 , 2 , Joseph Firth 1 , 3 Statistics from

2018 Evidence-Based Mental Health

34. Pharmacological interventions: Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia

Pharmacological interventions: Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) failure risk in patients with schizophrenia Article Text Commentary Pharmacological interventions Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia Jose M Rubio 1 , 2 , 3 , Christoph U Correll 1 , 2 , 3 , 4 Statistics from Altmetric.com Commentary on: Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA

2018 Evidence-Based Mental Health

35. Pharmacological interventions: L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia

Pharmacological interventions: L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia Article Text Commentary Pharmacological interventions L-methylfolate cannot yet be recommended as an add-on treatment

2018 Evidence-Based Mental Health

36. Schizophrenia

Schizophrenia Schizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Schizophrenia Last reviewed: February 2019 Last updated: June 2018 Summary An illness characterised by a co-occurrence of at least two of the following symptoms: hallucinations, delusions, disorganised speech, disorganised/catatonic behaviour, or negative symptoms occurring for a significant period of time during a 1-month period (...) and delusions to frank psychosis. Initially, patients are usually referred by family members. As the illness progresses, patients tend to self-refer or are brought in by a case manager or law enforcement officer. Antipsychotic therapy and psychosocial interventions are effective for most patients, but to varying degrees. Suicidal tendency is one of the most dangerous complications. The lifetime risk of suicide is around 5%. The risk is highest at the onset of the illness. Definition Schizophrenia

2018 BMJ Best Practice

37. Transcranial Magnetic Stimulation for Major Depression and Schizophrenia

Transcranial Magnetic Stimulation for Major Depression and Schizophrenia Transcranial Magnetic Stimulation for Major Depression and Schizophrenia An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017 An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017. This report was prepared by: Ma N, Atukorale Y, Duncan J, Marlow N, Cameron A Research and Evaluation, incorporating ASERNIP-S, Royal (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Ma N, Atukorale Y, Marlow N, Duncan J, Cameron A (2017) Transcranial Magnetic Stimulation for major depression and schizophrenia: an Evidence Check brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily

2018 Sax Institute Evidence Check

38. Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V

Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Cariprazin (Schizophrenie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A18-25 Cariprazine (schizophrenia) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-25 Version 1.0 Cariprazine (schizophrenia) 12 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cariprazine (schizophrenia) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

39. Second-generation antipsychotic injections for schizophrenia

Second-generation antipsychotic injections for schizophrenia '); } else { document.write(' '); } ACE | Second-generation antipsychotic injections for treating schizophrenia Search > > Second-generation antipsychotic injections for treating schizophrenia - Second-generation antipsychotic injections for treating schizophrenia Published on 1 October 2018 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has not recommended listing paliperidone or aripiprazole injections (...) on the Medication Assistance Fund (MAF) for treating schizophrenia, due to unacceptable cost-effectiveness compared with first-generation antipsychotic injections at the prices proposed by the manufacturers. Factors considered to inform the recommendations for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of injectable second-generation antipsychotics (SGAs)—paliperidone and aripiprazole injections

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

40. Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Full Text available with Trip Pro

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: NCT00628589, NCT00721955).To examine the five individual items (...) comprising the PANSS-EC and the percentage of patients achieving a clinical response (reduction of ≥40%) in PANSS-EC (Response-40) for these two studies.Response-40 was examined at the primary end-point (2 h) and over time.Response-40 and each PANSS-EC item score were statistically significant v. placebo at 2 h and at each assessment time point for both doses.Inhaled loxapine produced rapid improvement in agitated patients with schizophrenia or bipolar I disorder, achieving Response-40 at the first

2017 BJPsych open Controlled trial quality: uncertain